NLRP3 and metabolic dysfunction-associated steatohepatitis: In preclinical models, adropin demonstrates a protective role in diet-induced nonalcoholic steatohepatitis (NASH) by activating Nrf2 signaling and inhibiting NLRP3 inflammasome activation, suggesting its therapeutic potential in NASH prevention and treatment [118,119].